国产精品视频观看,又大又粗有色,琪琪吊操人妻日韩精品,欧美 国产 日韩成人

服務(wù)熱線

15021010459
技術(shù)文章
當(dāng)前位置:主頁 > 技術(shù)文章 > 賽諾菲投資7億美元支持Alnylam開發(fā)RNAi療法

賽諾菲投資7億美元支持Alnylam開發(fā)RNAi療法

更新時間:2014-01-14 點擊次數(shù):1594

    2014年1月14日賽諾菲宣布將擴大與Alnylam公司在RNAi研究領(lǐng)域的合作。公司將投入約7億美元收購Ainylam公司約12%的股份以支持其目前處于研發(fā)階 段的各種研究項目。這一動作同時也標(biāo)志著賽諾菲在波士頓地區(qū)繼續(xù)擴大影響。公司此前以200億美元的價格收購了Genzyme公司,而Genzyme公司將與Ainylam在RNAi領(lǐng)域開始密切配合。

    事實上,不僅僅是賽諾菲,一些制藥*都已經(jīng)開始表現(xiàn)出重返RNAi療法研究的跡象。例如羅氏公司剛剛簽訂了第二份關(guān)于RNAi研究的合作協(xié)議。這些跡象都暗示著今后這些醫(yī)藥研發(fā)*將可能向RNAi療法這一研究領(lǐng)域投入巨大精力。

詳細英文報道:

Sanofi is doubling down on its RNAi development deal with Alnylam. The pharma giant ($SNY) says it will pay a hefty premium to buy up a 12% stake in the biotech, investing $700 million and greatly expanding its rights to Alnylam's ($ALNY) lead drug along with a portfolio of current and prospective therapies.

The deal highlights Big Pharma's return to RNAi, a new technology for gene silencing that experienced a deep chill several years ago as Roche ($RHHBY) and others bowed out of the field. But Roche recently struck its second RNAi pact and Sanofi clearly believes that the industry is nearing some critical product-development milestones.

The expanded partnership also spotlights Sanofi's growing involvement in the Boston hub, where it paid $20 billion for Genzyme and its rare disease drugs. Now the Genzyme subsidiary will work with Alnylam on patisiran, in development for TTR-familial amyloid polyneuropathy, gaining marketing rights outside of North America and Europe. Sanofi also gains marketing rights to three other therapies in the pipeline while nabbing options on all other products that treat rare diseases.

Alnylam execs have been one of the chief proponents of RNAi as the next big product arena, with potential to rival monoclonal antibodies in terms of revenue potential. And they clearly relished the opportunity to boast about the new deal at the beginning of the big JPMorgan conference in San Francisco.

"RNAi therapeutics now have the opportunity to be the next product platform," Alnylam COO Barry Greene told Reuters.——(華雅干細胞整理報道)

2025 版權(quán)所有 © 重慶市華雅干細胞技術(shù)有限公司  備案號:渝ICP備14000349號-4 sitemap.xml 管理登陸 技術(shù)支持:化工儀器網(wǎng)

地址:重慶市江北區(qū)金渝大道153號8棟20-14 傳真:023-63419626 郵件:sales@ys-bio.com

重慶市華雅干細胞技術(shù)有限公司主要經(jīng)營干細胞研究 干細胞治療產(chǎn)品 生物試劑 實驗耗材 藥物研發(fā)等產(chǎn)品。

關(guān)注我們

服務(wù)熱線

400-021-2200

掃一掃,關(guān)注我們

国产97人人超碰caoProm| 欧洲人妻丰满AV无码久久不卡| 久久激情综合网| 欧美精品婷婷| yase视频国产精品| 中文字幕日韩精品熟女少妇| 一色导航| 丁香五月激情六月婷婷| 本道αV第1页亚洲国产欧美| 色呦呦白塔视频| 国产成人免费| 亚州图片一区二区三区| 乱片福利导航| 2021自拍偷在线精品自拍偷| 流白浆网址| 黄片一区二区三区四区五区六区| 一级特黄在线观看| 亚洲精品人成网线在线va| 图片区网友自拍日韩欧美| 午夜av福利电影| 日本成人大色堂| 亚洲免费黄色毛片| 亚洲欧美韩精品| 少妇无码太爽了不卡视频在线看| 国产人妖久久久| www涩涩com| 久久免费视频免费视频| 亚州Av无码大片一区二区| 久久婷婷色五月综合啪| 蜜桃爆乳无码av| 中文字幕允奶头| 久久69精品无码一区二区国产盗| 综合九九精品伊人| 午夜福利无码1000久久| 亚洲成人综合图片| 99热这里都是精品| 久久人人爽人人爽人人片Ⅴ| 国产精品三p一区二区| 99爱精品视频| 啊啊啊啊啊一区二区| 国产精品亚洲精品毛片完整版|